GSK/SkyePharma’s Requip XL Has Mid-December Action Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended-release ropinirole uses Skye’s proprietary GeoMatrix technology to provide steady levels over 24 hours.
You may also be interested in...
GSK Receives Approvable Letter For Once-Daily Formulation Of Requip
Extended-release version will reduce Parkinson’s disease patients’ “off time” by about two hours a day, clinical data show.
GSK Receives Approvable Letter For Once-Daily Formulation Of Requip
Extended-release version will reduce Parkinson’s disease patients’ “off time” by about two hours a day, clinical data show.
GSK 14-Hour Requip CR “Approvable,” FDA Says
The company is “committed” to working with FDA to determine the best path forward.